- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Multicenter, Randomized, Double-blind, Placebo‑controlled Study with Deferred Active Treatment to Investigate the Efficacy, Safety, and Pharmacokinetics of JNJ‑73763989 + Nucleos(t)ide Analog in Participants Co‑infected with Hepatitis B and Hepatitis D Virus
This study is looking into a new treatment, JNJ-73763989, for people who have both Hepatitis B and Hepatitis D. It aims to see how well it works, if it's safe, and how the body handles it, compared to a dummy treatment.
For: Hepatitis B and Hepatitis D Viral Co-infectionSweden · Italy · France - Ongoing, recruitingTherapeutic exploratory (Phase II)
An open-label, non-randomized, biopsy-based mechanistic study on pharmacokinetics, pharmacodynamics, safety and tolerability of ianalumab in patients with Sjögren's syndrome
This study is looking at a new medicine called ianalumab for Sjögren's syndrome. We want to see how it affects cells in the salivary glands, how safe it is, and how the body uses it. This is an early-stage study.
For: Sjögren's syndromeFrance - AuthorisedTherapeutic exploratory (Phase II)
Exploratory Study of Ianalumab in Adults with Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) who Have Previously Benefited from Ianalumab (VAY RE-HIT)
This study looks at a medicine called ianalumab for adults with certain blood conditions (ITP or wAIHA). It wants to see if the medicine continues to work well for those who have used it before, aiming to understand its long-term benefits.
For: Immune thrombocytopenia (ITP) Warm autoimmune hemolytic anemia (wAIHA)Germany · Czechia · Belgium